DARE-HPV development supported by $10 million ARPA-H contract; program targets major unmet need with no FDA-approved therapies ...
Polaryx Therapeutics Inc. PLYX shares are up on Tuesday as the company has made significant strides in advancing its clinical programs. The positive movement follows the announcement that Polaryx has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results